Table 1 Patient characteristics.
Patient characteristics at venetoclax initiation | n = 76 |
|---|---|
Age (years), median (range) | 66 (38–91) |
Age >65 years, n (%) | 43 (58) |
Gender, Male n (%) | 45 (59) |
ECOG performance status, n (%) | |
0–1 | 60 (84.5) |
2–3 | 11 (15.5) |
Serum monoclonal protein, n (%) | |
IgM | 62 (89) |
IgG/IgA | 6 (9) |
Absent | 2 (3) |
Serum IgM Level | |
Median, range | 2,409 (5–9300) |
≥4000 mg/dL, n (%) | 22 (32) |
Hemoglobin level (g/dL) | |
Median, range | 10 (6-16) |
≤11.5 d/dL, n (%) | 53 (72) |
Platelets (K/µL) | |
Median, range | 183 (5–526) |
≤100, n (%) | 17 (23) |
Serum B2 microglobulin level | |
Median, range | 2 (0–13) |
>3.0 g/dL, n (%) | 16 (43) |
BM involvement % | |
Median (range) | 60 (0–92) |
≥50%, n (%) | 32 (70) |
IPSSWM Score (at diagnosis), n (%) | |
High risk | 6 (9) |
Intermediate risk | 36 (55) |
Low risk | 24 (36) |
Genetic mutations (at any time point before venetoclax initiation) | |
MYD88 L265P | 65 (94) |
CXCR4 | 23 (40) |
TP53 | 10 (22) |
